Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
10 angezeigte Treffer · Seite 5, keine Gesamtzahl für „Xalkori“
Suchtreffer
Begriffe & Kennungen
Xalkori · 4.8 · The data described below reflect exposure to XALKORI in 1669 patients with ALK-positive advanced NSCLC who par
Eintrag öffnenXalkori · 4.8 · The median duration of treatment for paediatric patients with ALK-positive ALCL was 5.1 months. Permanent disc
Eintrag öffnenXalkori · 4.8 · The median duration of treatment for paediatric patients with ALK-positive IMT was 21.8 months. Permanent disc
Eintrag öffnenXalkori · 4.8 · The median duration of treatment for paediatric patients with all tumour types was 2.8 months. Permanent disco
Eintrag öffnenXalkori · 4.8 · The most frequent adverse reactions (≥3%, all-causality frequency) associated with dosing interruptions were n
Eintrag öffnenXalkori · 4.8 · The most serious adverse reactions in 1722 patients with either ALK-positive or ROS1-positive advanced NSCLC w
Eintrag öffnenXalkori · 4.8 · The safety analysis population for 110 paediatric patients with all tumour types (ages 1 to <18 years), which
Eintrag öffnenXalkori · 4.8 · The safety profile of crizotinib in paediatric patients with ALK-positive ALCL or with ALK-positive IMT was ge
Eintrag öffnenXalkori · 4.8 · Transaminase elevations generally occurred within the first 2 months of treatment. Across studies with crizoti
Eintrag öffnenXalkori · 4.8 · Visual effects Ophthalmological evaluation is recommended if vision disorder persists or worsens in severity.
Eintrag öffnen